Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

• Status: Active, not recruiting
• Trial end date: 2021-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This pilot phase I trial studies the side effects of engineered donor stem cell transplant in treating patients with hematologic malignancies. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Using T cells specially selected from donor blood in the laboratory for transplant may stop this from happening.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Antibodies; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Immunoglobulins; Lenograstim; Mechlorethamine; Melphalan; Nitrogen Mustard Compounds; Rituximab; Tacrolimus; Vidarabine

Criteria

Inclusion Criteria:

• Lack of a human leukocyte antigen (HLA) matched related donor, lack of an immediately available 8/8 HLA matched unrelated donor

• Patients must be diagnosed with a high-risk and/or advanced hematologic malignancy defined as one of the following

• Acute lymphocytic leukemia (ALL) in complete remission (CR)1 with high-risk features including adverse cytogenetic such as t(9;22), t(1;19), t(4;11), or MLL gene rearrangements; in second or greater morphologic remission; persistent minimal residual disease

• Acute myeloid leukemia (AML) in CR1 with intermediate-risk disease and persistent detectable minimal residual disease (MRD), or with high-risk features defined as: greater than 1 cycle of induction therapy required to achieve remission; preceding myelodysplastic syndrome (MDS) or myeloproliferative disease; presence of FLT3 mutations or internal tandem duplications, DNMT3a, TET2, MLL-partial tandem duplication (PTD), ASXL1, PHF6; FAB M6 or M7 classification; adverse cytogenetics including: -5, del 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8, complex (> 3 abnormalities)

• Patients with AML must have less than 10% bone marrow blasts and < 100/mcL absolute peripheral blood blast count

• Patients with AML in CR2, subsequent CR or with active disease at transplant (< 10% bone marrow blasts)

• MDS with International Prognostic Scoring System (IPSS) intermediate-2 or higher, therapy-related MDS or chronic myelomonocytic leukemia (CMML)

• Aplastic anemia with absolute neutrophil count (ANC) < 1,000 and transfusion dependent after failed immunosuppression therapy

• Chronic myeloid leukemia (CML) >= 1st chronic phase, after failed >=2 lines of tyrosine kinase inhibitors; patients who progressed to blast phase must be in morphologic remission at transplant

• Relapsed Hodgkin's disease or non-Hodgkin's lymphoma (NHL)

• Patients with chemo-sensitive chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with persistent or recurrent disease after fludarabine-based regimens with < 25% involvement by CLL/SLL cells

• Patients with lymphoblastic lymphoma in remission or after partial response to chemotherapy

• Patients with poor prognosis multiple myeloma by cytogenetics del13, del 17p, t(4;14) or t(14;16) or hypodiploidy, with advanced disease (stage >= 2) and /or relapsed after autologous stem cell transplant

• Zubrod performance status 0-1 or Karnofsky performance status > 70%; patients > 50 years will have to have a Sorror Comorbidity Index =< 3

• Available haploidentical donor willing and eligible to undergo a peripheral blood collection

• Left ventricular ejection fraction (LVEF) > 40%

• Bilirubin =< 1.5 mg/dl (unless Gilbert's syndrome), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 200 IU/ml for adults; conjugated (direct) bilirubin < 2 x upper limit of normal

• Serum creatinine clearance >= 50 ml/min (calculated with Cockcroft-Gault formula)

• Diffusing capacity for carbon monoxide (DLCO) >= 45% predicted corrected for hemoglobin

• Patient or patient's legal representative must provide written informed consent

Exclusion Criteria:

• Human immunodeficiency virus (HIV) positive; active hepatitis B or C

• Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility

• Liver cirrhosis with greater than grade 1 stage 1 inflammation/fibrosis

• Uncontrolled central nervous system (CNS) involvement by tumor cells within the past 2 months

• History of another primary malignancy that has not been in remission for at least 3 years; (the following are exempt from the 3-year limit: nonmelanoma skin cancer, fully excised melanoma in situ [stage 0], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear)

• Positive beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization

• Inability to comply with medical therapy or follow-up